Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- spinal cord injury occurred at least 3 months earlier - completed inpatient rehabilitation and living in the community

•experiencing chronic neuropathic pain for three months or more - for people of child-bearing potential: currently practicing an effective form of two types of birth control

Exclusion Criteria:

- progressive myelopathy secondary to posttraumatic cord tethering or syringomyelia - brain injury or cognitive impairment limiting the ability to follow directions - women who are pregnant or breastfeeding - medical and mental health diagnosis that may interfere with study drug (study staff will review)

Conditions & Interventions

Interventions:
Drug: Placebo, Drug: brivaracetam
Conditions:
Brain & Nervous System
Keywords:
Neuropathic Pain, Spinal Cord Injuries

More Information

Description: The purpose of this research study is to test the efficacy of the study drug, Brivaracetam, to reduce nerve pain in SCI. We also want to determine whether Brivaracetam impacts mood, brain, and genes to help us design more research with this study drug in the future. We will assign you randomly to one of 2 groups: the group that receives the active study drug (Brivaracetam) or the group that receives a placebo (sugar pill). There is a 50-50 chance that you will be assigned to one group or the other, similar to flipping a coin. Participation in this study will last approximately 11 weeks and will include 3 study visits to the study site; however, participation in the study can also be entirely virtual which would require no visits to the study site.
Study Contact: Ana Lucia Battaglino - abattagl@umn.edu
Principal Investigator: Ricardo Battaglino
Phase: Phase 3
IRB Number: SITE00001486